There are currently 1283 clinical trials in Miami, Florida looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Miami, GSK Investigational Site, University of Miami Miller School of Medicine-Sylvester Cancer Center and University of Miami Miller School of Medicine. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
NCT06283966
Recruiting
This study will evaluate the effect of triple ICS/LAMA/LABA therapy with BGF MDI 320/14.4/9.6 μg on cardiopulmonary outcomes relative to LAMA/LABA therapy with GFF MDI 14.4/9.6 μg in a population with COPD and elevated cardiopulmonary risk.
Gender:
ALL
Ages:
Between 40 years and 80 years
Trial Updated:
07/18/2025
Locations: Research Site, Miami, Florida +2 locations
Conditions: COPD (Chronic Obstructive Pulmonary Disease)
Register for Updates
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
NCT06876662
Recruiting
Study J2N-MC-JZ01 (JZ01) is an individual-study appendix (ISA) under master protocol J2N-MC-JZNY, and represents participants from the completed originator study, clinical study LOXO-BTK-18001/J2N-OX-JZNA. Participants in the originator study will have the opportunity to continue their assigned study intervention or continue their follow-up visits by transitioning to this study. This study will evaluate the long-term safety and efficacy of pirtobrutinib.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/18/2025
Locations: Sylvester Comprehensive Cancer Center, Miami, Florida
Conditions: Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma
Register for Updates
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
NCT06876649
Recruiting
The master protocol study J2N-MC-JZNY provides a framework to enable the evaluation of the long-term safety and efficacy of pirtobrutinib after completion of clinical studies evaluating pirtobrutinib. The clinical studies that will feed into this master protocol are referred to as originator studies. The master protocol will govern individual study-specific appendices (ISAs) that will represent participants from the individual, completed originator studies. These participants will have the oppor... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/18/2025
Locations: Sylvester Comprehensive Cancer Center, Miami, Florida
Conditions: Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma
Register for Updates
A Study to Assess the Efficacy and Safety of Lorundrostat in Participants With Obstructive Sleep Apnea and Hypertension
NCT06785454
Recruiting
The primary purpose of the study is to assess the effect of lorundrostat taken orally (po) once a day on the Apnea-Hypopnea Index (AHI) in participants with moderate to severe obstructive sleep apnea (OSA) and hypertension.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
07/18/2025
Locations: PharmaDev Clinical Research Institute, LLC, Miami, Florida
Conditions: Obstructive Sleep Apnea, Hypertension
Register for Updates
ExCrossV Multi Site Trial for Vascularized High Risk Keratoplasty
NCT06753916
Recruiting
The main objective of this study is to determine the safety of Ex Vivo Cross Linking (CXL) of donor corneal tissue in participants who have undergone high-risk penetrating keratoplasty.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2025
Locations: University of Miami - Bascom Palmer Eye Institute, Miami, Florida
Conditions: Corneal Transplant Failure
Register for Updates
Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
NCT06559306
Recruiting
The purpose of this study is to know how well seltorexant works, and also to evaluate safety and maintenance effect of seltorexant compared with placebo as an adjunctive therapy to an antidepressant in improving depressive symptoms in participants with major depressive disorder with insomnia symptoms (MDDIS) who have had an inadequate response to current antidepressant therapy with a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI).
Gender:
ALL
Ages:
Between 18 years and 74 years
Trial Updated:
07/17/2025
Locations: Pharmax Research Clinic Inc, Miami, Florida +2 locations
Conditions: Depressive Disorder, Major
Register for Updates
A Study of Assessment on Safety and Effectiveness of BWI Pulsed Field Ablation With OMNYPULSE Catheter for the Treatment of Paroxysmal Atrial Fibrillation (PAF)
NCT06455098
Recruiting
The purpose of this study is to demonstrate the safety and 12-month effectiveness of the BWI OMNYPULSE™ pulsed field ablation (PFA) platform for pulmonary vein isolation (PVI) in the treatment of participants with symptomatic paroxysmal atrial fibrillation (PAF), an irregular heart rate that causes abnormal blood flow.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
07/17/2025
Locations: HCA Florida Mercy Hospital, Miami, Florida
Conditions: Atrial Fibrillation
Register for Updates
CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D)
NCT06783309
Recruiting
This study is a Phase 1b/2a First-in-Human (FIH) clinical trial to assess the safety, tolerability, pharmacodynamics (PD), and efficacy of multiple ascending doses of CNP-103. The approximately 208-day study consists of a Screening Period (28 days), Treatment Period (90 days), and Post-Dose Evaluations (90 days).
Gender:
ALL
Ages:
Between 12 years and 35 years
Trial Updated:
07/17/2025
Locations: DY Professional Research Center, Miami, Florida
Conditions: Type 1 Diabetes Mellitus, T1D, T1DM, T1DM - Type 1 Diabetes Mellitus, Type 1 Diabetes in Adolescence, Type 1 Diabetes in Children, Type 1 Diabetes (Juvenile Onset), Type 1 Diabetes, Type 1 Diabetes Patients, Type 1 Diabetes Mellitis
Register for Updates
A Study of Lepodisiran (LY3819469) in Participants With Normal, Mild, Moderate, or Severe Liver Function
NCT06916078
Recruiting
The main purpose of this study is to evaluate how much lepodisiran gets into the blood stream and how long it takes the body to get rid of it when given as a subcutaneous (SC) injection under the skin to participants with mild, moderate, or severe liver function impairment compared to participants with normal liver function. The study will also evaluate how well lepodisiran is tolerated and what side effects may occur in these participants. The study will last up to approximately 9 weeks, exclu... Read More
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
07/17/2025
Locations: Clinical Pharmacology of Miami, Miami, Florida
Conditions: Liver Dysfunction, Healthy
Register for Updates
ctDNA to Predict Response to Chemo-Immunotherapy and Detect Minimal Residual Disease in Non-Small Cell Lung Cancer
NCT06902272
Recruiting
The purpose of this study is to determine if a blood test called circulating tumor DNA (ctDNA) can be used to predict how well patients will respond to treatment and if there is any cancer left after surgery. The investigators will also study if a drug called pembrolizumab can help prevent the cancer from coming back in patients who are ctDNA-positive or who have evidence of cancer after treatment and surgery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2025
Locations: University of Miami, Miami, Florida
Conditions: Non Small Cell Lung Cancer
Register for Updates
VY7523-102: Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study in Participants With Early Alzheimer's Disease
NCT06874621
Recruiting
This study is to be conducted in participants with early Alzheimer's Disease to test VY7523, a new drug being researched for treatment of Alzheimer's Disease. This study will look at how safe the drug is and how it works in the brain. It was first tested in normal, healthy participants who volunteered to participate. The study will look at three different dose levels, starting with the lowest dose first and moving to higher doses and more participants after safety has been reviewed by doctors an... Read More
Gender:
ALL
Ages:
Between 50 years and 90 years
Trial Updated:
07/17/2025
Locations: VYGR Site 840015, Miami, Florida +2 locations
Conditions: Alzheimer's Disease (AD)
Register for Updates
A Study to Investigate the Efficacy and Safety of Lebrikizumab in Participants With Moderate-to-Severe Atopic Hand and Foot Dermatitis
NCT06921759
Recruiting
The main purpose of this study is to assess the efficacy of lebrikizumab versus placebo on skin lesions in adults and adolescent participants with atopic hand and foot dermatitis. This study lasts up to 32 weeks, including a 6-week screening period, a 16-week treatment period, and a safety follow-up visit 12 weeks after the last dose.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
07/17/2025
Locations: Research Associates of South Florida - Miami - Southwest 8th Street, Miami, Florida
Conditions: Atopic Hand and Foot Dermatitis
Register for Updates